---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-036001"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2022-12-20T23:59:59+00:00"
generated_at: "2026-06-21T01:49:36.884269+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics reports Q2/Q3 2022 revenue $4.2M each; appliance units up 28% and 20% YoY

## Summary
- Q2 revenue $4.2M, Q3 revenue $4.2M; net income not disclosed due to revenue recognition policy change.
- Appliance arches sold: 3,321 (Q2, +28% YoY) and 3,057 (Q3, +20% YoY).
- Gross margin fell to 62% (Q2) and 59% (Q3) from 81% and 70% in prior year periods.
- Cash and equivalents $6.7M at Sept 30, 2022; company targeting positive cash flow in 12-18 months.
- Operational highlights include TGA clearances for oral appliances in Australia and strategic billing partnership with Nexus Dental.

## SEC filing metadata
- accession: 0001493152-22-036001
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2022-12-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315222036001/0001493152-22-036001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315222036001/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-036001
- JSON: https://secwatch.observer/filing/0001493152-22-036001.json
- Plain text: https://secwatch.observer/filing/0001493152-22-036001.txt

## Key facts
- Earnings Releases
  Vivos Therapeutics, Inc. reported the second quarter of 2022 results: revenue $4.2 million.
  - Period: the second quarter of 2022
  - Revenue: $4.2 million
  - Result: reported results
  source text: Revenue was $4.2 million for the second quarter of 2022 and $7.8 million for the six months ended June 30, 2022, compared to $4.5 million and $7.9 million for the three and six months ended June 30, 2021, respectively, which in part reflects a deferral of a portion of revenue into future periods under Vivos’ new revenue recognition policies;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315222036001/0001493152-22-036001-index.htm
- Earnings Releases
  Vivos Therapeutics, Inc. reported the third quarter of 2022 results: revenue $4.2 million.
  - Period: the third quarter of 2022
  - Revenue: $4.2 million
  - Result: reported results
  source text: Revenue was $4.2 million for the third quarter of 2022 and $12.1 million for the nine months ended September 30, 2022, compared to $4.5 million and $12.5 million for the three and nine months ended September 30, 2021, respectively, which similarly in part reflects a deferral of a portion of revenue into future periods under Vivos’ new revenue recognition policies;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315222036001/0001493152-22-036001-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.